Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.
Share with a colleague
Pharmaceutical Executive Europe  E-News
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecutive
 
Survey
What is the primary social media tool you use for drug development research?
LinkedIn 30%

Facebook

12%
Twitter 12%
Google+ 8%
Chat rooms 4%
Article comments 19%
Blogs 15%

Talk to us:
jupton@advanstar.com

Advertise with us:
Dtaylor-higgins@advanstar.com

30 August, 2013
Pharm Exec Global Digest — Market Access Special
In the new issue: Develop a Market Access Roadmap; Embed Market Access in Your Organizational Culture; Initiating Early Access Programs in Europe; and More! ...Read more
How to Win in the Diabetes Space
Novo Nordisk's SVP of national diabetes sales tells PharmExec's Ben Comer about a new field force technology initiative, implications of the Sunshine Act, and why Victoza sales won’t slow down anytime soon ... Read more
Behind the Buzzwords, Patient Personas are Powerful
Peter Houston looks at the new marketing phrase that’s causing a stir — Direct to Persona — and asks whether it will make it beyond buzzword status to become an established approach ... Read more
Making Social Media Sell
Pharma companies have been widely embracing social media to advertise products, recruit staff, and report on CSR projects. But it is it doing any good, asks Patrick Homer ... Read more
The Truth Behind the China Bribery Scandals
The last few weeks have seen the media swamped with stories about the rampant bribery clawing at the pharmaceutical industry in China. And many believe that it is just the tip of the iceberg, writes Adeline Siew ... Read more
Products/Services Profiles
Sciformix
SciVigilance – Pharmacovigilance in a box
Scivigilance provides the powerful combination of streamlined processes, domain expertise and robust technology that integrates disparate data and enables the seamless flow, collection processing and analysis of data.  Scivigilance delivers significant time and cost savings, efficiency and compliance gains, all while delivering the highest quality outcomes. Read More
Also in this issue
Successful Social Communications: The What vs. The How
Specialty Drugs: A Tempting Target, But What to Do?
SPOs: Their Rise to Prominence